Spoonbill Pushes FDA for 4'-PPT in Special Medical Diets
Published Date: 7/29/2025
Proposed Rule
Summary
The Spoonbill Foundation asked the FDA to approve a new nutrient called 4'-phosphopantetheine (4'-PPT) for use in medical foods. If approved, this change will help people who rely on special medical diets get safer, better nutrition. The FDA is now reviewing the petition, and any updates could affect medical food makers and patients soon.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
FDA Reviewing 4'-PPT for Medical Foods
The FDA has filed a petition to allow 4'-phosphopantetheine (4'-PPT) to be used as a nutrient in medical foods. If approved, this could help people who rely on special medical diets get safer, better nutrition.
Potential Impact on Medical Food Makers
The petition proposes amending food additive rules to permit 4'-PPT in medical foods, which could change what medical food makers are allowed to use. The FDA review and any future regulatory update could affect medical food manufacturers.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-14335 — APIX Biosciences US LLC; Filing of Food Additive Petition (Animal Use)
APIX Biosciences wants the FDA to approve using cholesterol safely in honeybee food. This change could help beekeepers feed their bees better, keeping them healthy. If approved, it might start soon and won’t cost extra for most folks, but it’s a big win for buzzing buddies everywhere!
Next: 2025-14342 — Takes of Marine Mammals Incidental to Specified Activities; Taking Marine Mammals Incidental to Alaska LNG Project in Cook Inlet
The Alaska LNG Project in Cook Inlet wants permission to accidentally affect some marine mammals while working from 2026 to 2030. NMFS is proposing rules to protect these animals as much as possible and wants your thoughts before making a final decision. This plan balances energy progress with caring for wildlife, and it could impact how the project operates and reports its activities.